JPMorgan Chase & Co. started coverage on shares of Generation Bio (NASDAQ:GBIO) in a research report issued to clients and investors on Tuesday, Briefing.com Automated Import reports. The firm set an “overweight” rating and a $28.00 price target on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 43.15% from the stock’s current price.
Other research analysts have also recently issued research reports about the stock. Wedbush initiated coverage on shares of Generation Bio in a report on Tuesday. They issued an “outperform” rating and a $31.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Generation Bio in a report on Tuesday. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Cowen initiated coverage on shares of Generation Bio in a report on Tuesday. They issued an “outperform” rating on the stock.
Shares of Generation Bio stock opened at $19.56 on Tuesday. Generation Bio has a 52-week low of $18.51 and a 52-week high of $24.90.
Generation Bio Company Profile
Generation Bio Co develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co was formerly known as Torus Therapeutics, Inc and changed its name to Generation Bio Co in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Featured Article: What are popular range trading strategies?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.